Success Metrics

Clinical Success Rate
75.0%

Based on 12 completed trials

Completion Rate
75%(12/16)
Active Trials
13(33%)
Results Posted
83%(10 trials)
Terminated
4(10%)

Phase Distribution

Ph phase_4
2
5%
Ph phase_3
8
20%
Ph early_phase_1
1
3%
Ph not_applicable
11
28%
Ph phase_1
5
13%
Ph phase_2
11
28%

Phase Distribution

6

Early Stage

11

Mid Stage

10

Late Stage

Phase Distribution38 total trials
Early Phase 1First-in-human
1(2.6%)
Phase 1Safety & dosage
5(13.2%)
Phase 2Efficacy & side effects
11(28.9%)
Phase 3Large-scale testing
8(21.1%)
Phase 4Post-market surveillance
2(5.3%)
N/ANon-phased studies
11(28.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

12 of 20 finished

Non-Completion Rate

40.0%

8 ended early

Currently Active

13

trials recruiting

Total Trials

40

all time

Status Distribution
Active(15)
Completed(12)
Terminated(8)
Other(5)

Detailed Status

Completed12
Recruiting9
Terminated4
Withdrawn4
unknown4
Active, not recruiting4

Development Timeline

Analytics

Development Status

Total Trials
40
Active
13
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.6%)
Phase 15 (13.2%)
Phase 211 (28.9%)
Phase 38 (21.1%)
Phase 42 (5.3%)
N/A11 (28.9%)

Trials by Status

terminated410%
withdrawn410%
completed1230%
recruiting923%
unknown410%
enrolling_by_invitation13%
not_yet_recruiting13%
active_not_recruiting410%
suspended13%

Recent Activity

Clinical Trials (40)

Showing 20 of 40 trialsScroll for more
NCT07438496Phase 3

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Recruiting
NCT06741969Phase 3

Nipocalimab in Moderate to Severe Sjogren's Disease

Active Not Recruiting
NCT07361302Phase 3

A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

Recruiting
NCT03439865Early Phase 1

Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis

Recruiting
NCT06193889Phase 2

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Recruiting
NCT06693830Not Applicable

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Recruiting
NCT03738410Not Applicable

An mHealth Intervention to Improve Outcomes for Women With HIV/AIDS

Recruiting
NCT02756793Not Applicable

Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)

Active Not Recruiting
NCT06708000Phase 3

Personalized Evaluation of Susptected Myocardial Ischemia

Enrolling By Invitation
NCT04968912Phase 2

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

Completed
NCT07066163Not Applicable

SMART-PD: Evaluating the Impact of Smartphone-Based Wearable Technology on Motor Symptoms and Quality of Life in People With Parkinson's Disease

Not Yet Recruiting
NCT04908111Phase 1

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Suspended
NCT06976853Phase 2

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

Recruiting
NCT06320925

SportsPro: Post-Market Clinical Follow Up Study

Recruiting
NCT03562637Phase 3

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Active Not Recruiting
NCT03796793Not Applicable

Developing Strategies for Effective Debridement in Patients for Venous Leg Ulcers

Active Not Recruiting
NCT06158607Not Applicable

Pre-exposure Prophylaxis (PrEP) Adherence Intervention for Women with Substance Use Disorders

Recruiting
NCT03984188Phase 3

Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD

Completed
NCT05456802

Effect of Acute Cardiovascular Disease on Microbiome

Completed
NCT04404855Not Applicable

Antibiotic Selection Using Next Generation Sequencing vs Urine Culture

Completed

Drug Details

Intervention Type
DRUG
Total Trials
40